Prostate cancer: A model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model

Steroids

Volumn 73, Issue 9-10, 2008, Pages 1030-1037

  Bonaccorsi, Lorella ^a   Nosi, Daniele ^b   Quercioli, Franco ^c   Formigli, Lucia ^b   Zecchi, Sandra ^b   Maggi, Mario ^a   Forti, Gianni ^a   Baldi, Elisabetta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CNR   (Italy)

Author keywords

Androgen receptor; Lipid rafts; Prostate cancer

Indexed keywords

ADAPTOR PROTEIN; ANDROGEN; ANDROGEN RECEPTOR; CBL PROTEIN; CLATHRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MATRIGEL;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CARCINOGENESIS; CELL MEMBRANE; EARLY CANCER; FUSION GENE; GENOMICS; HUMAN; LIPID RAFT; LYSOSOME; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TMPRSS2 ERG FUSION GENE; UBIQUITINATION;

ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CHOLESTEROL; GENOME; HUMANS; LYSOSOMES; MALE; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; PHENOTYPE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 44649084345     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2008.01.028     Document Type: Article

References (51)

1. Bray F., Sankila R., Ferlay J., and Parkin D.M. Estimates of Cancer Incidence and Mortality in Europe in 1995. Eur J Cancer 38 (2002) 99-166
2. Rohel K.A., Han M., Ramos G.C., Antenor J.A.V., and Catalona W.J. Cancer progression and survival rates following Anatomical radical retropubic prostatectomy in 3478 consecutive patients: long term results. J Urol 172 (2004) 910-914
3. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., and Walsh P.C. Biochemical (Prostate Specific Antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523
4. Porter C.R., Kodama K., Gibbons R.P., Correa R., Chun F.K., Perrotte P., et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 176 (2006) 69-74
5. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
6. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448 (2007) 595-599
7. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436 (2005) 725-730
8. Cinar B., Koeneman K.S., Edlund M., Prins G.S., Zhau H.E., and Chung L.W. Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. Cancer Res 61 (2001) 7310-7317
9. Bonaccorsi L., Carloni V., Muratori M., Salvadori A., Giannini A., Carini M., et al. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 141 (2000) 3172-3182
10. Links Chuu C.P., Hiipakka R.A., Fukuchi J., Kokontis J.M., and Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 65 (2005) 2082-2084
11. Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, et al. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. FASEB J 2007 (Epub ahead of print).
12. Akashi T., Koizumi K., Nagakawa O., Fuse H., and Saiki I. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 16 (2006) 831-836
13. Berger R., Febbo P.G., Majumder P.K., Zhao J.J., Mukherjee S., Signoretti S., et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64 (2004) 8867-8875
14. Hendriksen P.J., Dits N.F., Kokame K., Veldhoven A., van Weerden W.M., Bangma C.H., et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66 (2006) 5012-5020
15. Joly-Pharaboz M.O., Ruffion A., Roch A., Michel-Calemard L., André J., Chantepie J., et al. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 73 (2000) 237-249
16. Nelius T., Filleur S., Yemelyanov A., Budunova I., Shroff E., Mirochnik Y., et al. Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 121 (2007) 999-1008
17. Yuan X., Li T., Wang H., Zhang T., Barua M., Borgesi R.A., et al. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169 (2006) 682-696
18. Hååg P., Bektic J., Bartsch G., Klocker H., and Eder I.E. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96 (2005) 251-258
19. Lyons L.S., and Burnstein K.L. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol 20 (2006) 1061-1072
20. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 (2001) 4315-4319
21. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
22. Han G., Buchanan G., Ittman M., Harris J.M., Yu X., DeMayo F.J., et al. Mutation of androgen receptor causes oncogenic transformation of the prostate. PNAS 102 (2005) 1151-1156
23. Taichman R.S., Loberg R.D., Mehra R., and Pienta K.J. The evolving biology and treatment of prostate cancer. J Clin Invest 117 (2007) 2351-2361
24. Singh P., Uzgare A., Litvinov I., Denmeade S.R., and Isaacs J.T. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 13 (2006) 653-666
25. Pienta K.J., and Smith D.C. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55 (2005) 300-318
26. Collins A.T., Berry P.A., Hyde C., Stower M.J., and Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65 (2005) 10946-10951
27. Pedram A., Razandi M., Sainson R.C., Kim J.K., Hughes C.C., and Levin E.R. A conserved mechanism for steroid receptor translocation to the plasma membrane. Biol Chem 282, 31 (2007) 22278-22288
28. Baron S., Manin M., Beaudoin C., Leotoing L., Communal Y., Veyssiere G., et al. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 279 (2004) 14579-14586
29. Castoria G., Lombardi M., Barone M.V., Bilancio A., Di Domenico M., Bottero D., et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 161 (2003) 547-556
30. Gatson J.W., Kaur P., and Singh M. Dihydrotestosterone differentially modulates the mitogen-activated protein kinase and the phosphoinositide 3-kinase/Akt pathways through the nuclear and novel membrane androgen receptor in C6 cells. Endocrinology 147 (2006) 2028-2034
31. Papakonstanti E.A., Kampa M., Castanas E., and Stournaras C. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 17 (2003) 870-881
32. Freeman M.R., Cinar B., and Lu M.L. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 16 (2005) 273-279
33. Cinar B., Mukhopadhyay N.K., Meng G., and Freeman M.R. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. Rapid signalling pathway activation by androgens in epithelial and stromal cells. J Biol Chem 282 (2007) 29584-29593
34. Zhuang L., Lin J., Lu M.L., Solomon K.R., and Freeman M.R. Cholesterol-rich lipid rafts mediate Akt-regulated survival in prostate cancer cells. Cancer Res 62 (2002) 2227-2231
35. Simons K., and Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1 (2000) 31-39
36. Lu M.L., Schneider M.C., Zheng Y., Zhang X., and Richie J.P. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 276 (2001) 13442-13451
37. Jagla M., Fève M., Kessler P., Lapouge G., Erdmann E., Serra S., et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 148 (2007) 4334-4343
38. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., and Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63 (2003) 1981-1989
39. Bakin R.E., Gioeli D., Bissonette E.A., and Weber M.J. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 15; 63 (2003) 1975-1980
40. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr Rev 25 (2004) 276-308
41. Zhoul J., Hernandez G., Tu S.W., Huang C.L., Tseng C.P., and Hsieh J.T. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res 65 (2005) 9906-9913
42. Bonaccorsi L., Carloni V., Muratori M., Formigli L., Zecchi S., Forti G., et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 20; 112 (2004) 78-86
43. Lange C.A., Gioeli D., Hammes S.R., and Marker P.C. Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu Rev Physiol 69 (2007) 171-199
44. Bonaccorsi L., Nosi D., Muratori M., Formigli L., Forti G., and Baldi E. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 38 (2007) 51-66
45. Oosterhoff J.K., Kühne L.C., Grootegoed J.A., and Blok L.J. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. Int J Cancer 113 (2005) 561-567
46. Sigismund S., Woelk T., Puri C., Maspero E., Tacchetti C., Transidico P., et al. Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 102 (2005) 2760-2765
47. Huang F., Kirkpatrick D., Jiang X., Gygi S., and Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol Cell 21 (2006) 737-748
48. Aguilar R.C., and Wendland B. Endocytosis of membrane receptors: two pathways are better than one. Proc Natl Acad Sci USA 102 (2005) 2679-2680
49. Lajoie P., and Nabi I.R. Regulation of raft-dependent endocytosis. J Cell Mol Med 11 (2007) 644-653
50. Park W.Y., Park J.S., Cho K.A., Kim D.I., Ko Y.G., Seo J.S., et al. Up-regulation of caveolin attenuates epidermal growth factor signalling in senescent cells. J Biol Chem 275 (2000) 20847-20852
51. Lambert S., Vind-Kezunovic D., Karvinen S., and Gniadecki R. Ligand-independent activation of the EGFR by lipid raft disruption. J Invest Dermatol 126 (2006) 954-956